You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 65 No. 7, July 2008 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Article
 •Online Features
 This Article
 •Full text
 •PDF
 •Supplemental Methods
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (48)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Neurology, Other
 •Psychiatry
 •Schizophrenia
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Reduced Cortical Cannabinoid 1 Receptor Messenger RNA and Protein Expression in Schizophrenia

Stephen M. Eggan, PhD; Takanori Hashimoto, MD, PhD; David A. Lewis, MD

Arch Gen Psychiatry. 2008;65(7):772-784.

Context  Cannabis use is associated with both impaired cognitive functions, including working memory, and an increased risk of schizophrenia. Schizophrenia is characterized by impairments in working memory that are associated with reduced {gamma}-aminobutyric acid (GABA) neurotransmission in the dorsolateral prefrontal cortex. The cannabinoid 1 receptor (CB1R) is highly expressed in the dorsolateral prefrontal cortex, is contained in the axon terminals of a subpopulation of perisomatic-targeting GABA neurons, and, when activated, suppresses the release of GABA.

Objective  To determine the potential relationship between CB1R signaling and altered GABA neurotransmission in schizophrenia by evaluating CB1R messenger RNA (mRNA) and protein expression in the dorsolateral prefrontal cortex.

Design  In situ hybridization and immunocytochemistry techniques were used to examine the cortical levels of CB1R mRNA and protein, respectively.

Setting  Brain specimens were obtained from autopsies conducted at the Allegheny County Medical Examiner's Office, Pittsburgh, Pennsylvania.

Participants  Postmortem brain specimens from 23 pairs of subjects with schizophrenia and age-, sex-, and postmortem interval–matched comparison subjects, as well as brain specimens from 18 macaque monkeys with long-term exposure to haloperidol, olanzapine, or placebo.

Main Outcome Measures  Optical density measures of CB1R mRNA expression and protein levels and correlations with previously reported glutamic acid decarboxylase 67 and cholecystokinin mRNA measures.

Results  Levels of CB1R mRNA were significantly lower by 14.8% in the subjects with schizophrenia. Similarly, CB1R protein levels, assessed by radioimmunocytochemistry and standard immunocytochemistry, were significantly decreased by 11.6% and 13.9%, respectively. Group differences in CB1R mRNA levels were significantly correlated with those in glutamic acid decarboxylase 67 and cholecystokinin mRNA levels. Expression of CB1R mRNA was not changed in antipsychotic-exposed monkeys, and neither CB1R mRNA levels nor protein levels were affected by potential confounding factors in the subjects with schizophrenia.

Conclusions  This combination of findings suggests the testable hypothesis that reduced CB1R mRNA and protein levels in schizophrenia represent a compensatory mechanism to increase GABA transmission from perisomatic-targeting cholecystokinin interneurons with impaired GABA synthesis.


Author Affiliations: Departments of Psychiatry (Drs Eggan, Hashimoto, and Lewis) and Neuroscience (Dr Lewis), University of Pittsburgh, Pittsburgh, Pennsylvania.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

This Month in Archives of General Psychiatry
Arch Gen Psychiatry. 2008;65(7):743.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dysfunctional Prefrontal Cortical Network Activity and Interactions following Cannabinoid Receptor Activation
Kucewicz et al.
J. Neurosci. 2011;31:15560-15568.
ABSTRACT | FULL TEXT  

Lamina-Specific Alterations in Cortical GABAA Receptor Subunit Expression in Schizophrenia
Beneyto et al.
Cereb Cortex 2011;21:999-1011.
ABSTRACT | FULL TEXT  

Postnatal Developmental Trajectories of Neural Circuits in the Primate Prefrontal Cortex: Identifying Sensitive Periods for Vulnerability to Schizophrenia
Hoftman and Lewis
Schizophr Bull 2011;37:493-503.
ABSTRACT | FULL TEXT  

Development of Cannabinoid 1 Receptor Protein and Messenger RNA in Monkey Dorsolateral Prefrontal Cortex
Eggan et al.
Cereb Cortex 2010;20:1164-1174.
ABSTRACT | FULL TEXT  

Substance Use Disorders in Schizophrenia--Clinical Implications of Comorbidity
Volkow
Schizophr Bull 2009;35:469-472.
ABSTRACT | FULL TEXT  

Gene-Environment Interplay Between Cannabis and Psychosis
Henquet et al.
Schizophr Bull 2008;34:1111-1121.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.